Wall Street brokerages expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to announce earnings per share of ($0.74) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Kiniksa Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($0.75). Kiniksa Pharmaceuticals posted earnings per share of ($0.51) in the same quarter last year, which indicates a negative year-over-year growth rate of 45.1%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($3.47) per share for the current fiscal year, with EPS estimates ranging from ($3.54) to ($3.40). For the next financial year, analysts expect that the business will post earnings of ($3.45) per share, with EPS estimates ranging from ($3.60) to ($3.30). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.03.

A number of equities analysts have issued reports on the company. ValuEngine upgraded Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wedbush reiterated a “buy” rating on shares of Kiniksa Pharmaceuticals in a research report on Wednesday. Zacks Investment Research upgraded Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Friday. Finally, JMP Securities lowered their price target on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating on the stock in a research report on Wednesday. They noted that the move was a valuation call. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $26.50.

A number of large investors have recently added to or reduced their stakes in the stock. First Manhattan Co. raised its stake in Kiniksa Pharmaceuticals by 68.3% in the second quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after buying an additional 25,970 shares in the last quarter. Citadel Advisors LLC increased its position in shares of Kiniksa Pharmaceuticals by 195.8% during the second quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock worth $5,041,000 after purchasing an additional 246,442 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Kiniksa Pharmaceuticals during the second quarter worth about $474,000. Morgan Stanley increased its position in shares of Kiniksa Pharmaceuticals by 54.2% during the second quarter. Morgan Stanley now owns 60,098 shares of the company’s stock worth $814,000 after purchasing an additional 21,130 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Kiniksa Pharmaceuticals by 14.4% during the second quarter. BlackRock Inc. now owns 1,107,091 shares of the company’s stock worth $14,990,000 after purchasing an additional 139,072 shares in the last quarter. Hedge funds and other institutional investors own 29.79% of the company’s stock.

KNSA stock traded up $0.58 during mid-day trading on Tuesday, reaching $9.99. 115,200 shares of the company’s stock were exchanged, compared to its average volume of 76,332. The company has a market cap of $514.74 million, a price-to-earnings ratio of -2.86 and a beta of -1.56. The stock’s 50 day moving average is $12.85 and its 200 day moving average is $15.45. Kiniksa Pharmaceuticals has a 12-month low of $9.08 and a 12-month high of $32.88.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Article: Growth and Income Funds

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.